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Background
Infliximab and adalimumab are monoclonal antibodies to
tumor necrosis factor alpha (TNF-á) used in the treatment
of various inflammatory disorders. Infliximab, a chimeric
monoclonal antibody, is postulated to be more immuno-
genic as it is not entirely humanized.
Despite reports of adalimumab treatment in patients
after an adverse reaction to infliximab, there is a paucity
of literature reporting the converse – treatment with
infliximab after adverse reaction to adalimumab. Thus, it
is difficult to estimate the risk of cross-sensitization.
Graded drug challenges are utilized for patients unlikely
to be allergic to a specific drug, but where concern for a
reaction remains.
Objective
To present a patient with Crohn’s disease and prior hyper-
sensitivity to adalimumab who successfully underwent a
graded intravenous challenge with infliximab.
Methods
The patient previously had acute generalized urticaria due
to adalimumab, with corresponding positive intradermal
skin tests. Because her bowel disease activity was severe,
her gastroenterologist preferred to start another anti-TNF
agent. Infliximab was the chosen alternative. She under-
went an infliximab-graded challenge in an outpatient clinic
staffed by trained allergists.
Results
The patient received infliximab during the graded chal-
lenge without adverse reactions.
Conclusions
This is the first case, to our knowledge, to demonstrate
an infliximab-graded challenge for a patient with a prior
reaction to adalimumab. For patients requiring TNF-á
inhibitors, but with previous reactions and concern for
cross-sensitization, a graded challenge with the first dose
of an alternate agent under observation by care providers
trained to manage adverse drug reactions, may be a safe
approach.
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